FDA CTP Releases Comprehensive Strategic Plan for Next 5 Years

Regulations by 2FIRSTS.ai

Dec.19.2023

FDA CTP Releases Comprehensive Strategic Plan for Next 5 Years

FDA's Center for Tobacco Products (CTP) released its comprehensive strategic plan, aiming to reduce the negative health impacts of tobacco use.

On December 18th, according to an announcement on the official website of the United States Food and Drug Administration (FDA), Brian King, the Director of the FDA Center for Tobacco Products (CTP), released a statement outlining the center's comprehensive strategic plan.

Previously, CTP responded to the evaluation conducted by the independent expert group organized by the Reagan-Udall Foundation, announcing the initiation of a brand new five-year strategic plan, which will be unveiled by the end of the year. Since then, the center has focused on the new strategic plan as its core task, actively seeking feedback from external stakeholders through public opinion surveys and hearings, in order to enhance its planning capabilities.

CTP's new strategic plan was officially unveiled today. The plan outlines how the organization will operate and manage its staff in the next five years. This strategic plan marks a new chapter for CTP, building upon the solid foundation it has established since its inception in 2009. Guided by this plan, CTP aims to reduce the adverse health impacts caused by tobacco use. This includes ensuring the regulated functioning of the market, preventing the initiation of tobacco use among the public, promoting smoking cessation among tobacco users, and minimizing the harms associated with tobacco product use.

During the development of this strategic plan, CTP also updated its vision and mission to accurately reflect its nature of work and guide future activities. These modifications emphasize the importance of CTP's public health priorities and advancing health equity. The strategic plan sets out five objectives, ten outcomes, and proposes several corresponding goals.

The CTP plans to achieve these goals and outcomes by issuing influential regulations, utilizing scientific methods for application review, implementing timely and impactful compliance and enforcement strategies, and educating the public about the risks associated with tobacco products.

Also Read:

[1] FDA Urged Reformation of PMTA Process

[2] FDA and CBP Seize 1.4 Million Unauthorized E-Cigarette Products

[3] US Congress Demand Action from Department of Justice and FDA to Stop Child-Friendly E-Cigs

#North America #United States #Traditional tobacco #Legislation #FDA #Comprehensive Tobacco Control Plan

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S FDA Announces Dec. 8 Deadline for IQOS MRTP Renewal Comments

The U.S. FDA has set December 8, 2025, 11:59 p.m. ET as the closing date for public comments on the MRTP renewal applications submitted by Philip Morris Products S.A. for several IQOS heated tobacco products.

Nov.07 by 2FIRSTS.ai

Philip Morris International and an Italian Design Brand Launch Limited-Edition IQOS Collaboration, Debuting in Japan Before Expanding to 13 Travel Retail Markets

Philip Morris International (PMI) has partnered with Italian design brand Seletti on a limited-edition IQOS collaboration, unveiled at Milan’s Pirelli HangarBicocca. The collection features two models, launching first in Japan before rolling out to 13 global travel retail markets. PMI says the partnership leverages design and cultural storytelling to advance its smoke-free transition.

Oct.28 by 2FIRSTS.ai

JUUL wins approval after FDA reversal of Marketing Denial Order

JUUL's regulatory journey from Marketing Denial Order to approval showcases FDA's evolving approach to e-cigarette oversight.

Nov.03 by 2FIRSTS.ai

Special Report | After the Shortage: How the U.S. Vape Market Is Rebuilding Itself

After a wave of regulatory crackdowns, the U.S. vaping market is undergoing a deep reshuffle — shortages sparked frenzy, and resupply triggered elimination. Through interviews with industry insiders from both China and the United States, 2Firsts reveals how the American market is rebuilding itself amid turbulence.